Evidence map›Paper›PMID 26082240›Full record

ArticleScientific reports2015

HIV-infected sex workers with beneficial HLA-variants are potential hubs for selection of HIV-1 recombinants that may affect disease progression.

Chih-Hao Chang, Nicolaas C Kist, Tammy L Stuart Chester, Vattipally B Sreenu, Melissa Herman, Ma Luo, Daniel Lunn, John Bell, Francis A Plummer, T Blake Ball and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Chih-Hao ChangMedical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Nicolaas C KistDepartment of Zoology, University of Oxford, South Parks Road, Oxford, United Kingdom.
Tammy L Stuart ChesterNational HIV and Retrovirology Laboratories, JC Wilt Infectious Disease Research Centre, Winnipeg, Manitoba, Canada.
Vattipally B SreenuMedical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
Melissa HermanDepartment of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada.
Ma Luo1] National HIV and Retrovirology Laboratories, JC Wilt Infectious Disease Research Centre, Winnipeg, Manitoba, Canada [2] Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada.
Daniel LunnDepartment of Statistics, University of Oxford, Oxford, United Kingdom.
John BellOffice of the Regius Professor of Medicine, The Richard Doll Building, University of Oxford, Oxford, United Kingdom.
Francis A PlummerDepartment of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada.
T Blake Ball1] National HIV and Retrovirology Laboratories, JC Wilt Infectious Disease Research Centre, Winnipeg, Manitoba, Canada [2] Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada [3] Department of Immunology, University of Manitoba, Winnipeg, MB, Canada.
Aris KatzourakisDepartment of Zoology, University of Oxford, South Parks Road, Oxford, United Kingdom.
Astrid K N Iversen1] Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom [2] Nuffield Department of Clinical Neurosciences, Division of Clinical Neurology, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
University of Oxford · GBUniversity of Manitoba · CACanadian Science Centre for Human and Animal Health · CAMedical Research Council · GB

Funding

Medical Research Council G0801822
6 · The paper itself

Abstract

Cytotoxic T lymphocyte (CTL) responses against the HIV Gag protein are associated with lowering viremia; however, immune control is undermined by viral escape mutations. The rapid viral mutation rate is a key factor, but recombination may also contribute. We hypothesized that CTL responses drive the outgrowth of unique intra-patient HIV-recombinants (URFs) and examined gag sequences from a Kenyan sex worker cohort. We determined whether patients with HLA variants associated with effective CTL responses (beneficial HLA variants) were more likely to carry URFs and, if so, examined whether they progressed more rapidly than patients with beneficial HLA-variants who did not carry URFs. Women with beneficial HLA-variants (12/52) were more likely to carry URFs than those without beneficial HLA variants (3/61) (p < 0.0055; odds ratio = 5.7). Beneficial HLA variants were primarily found in slow/standard progressors in the URF group, whereas they predominated in long-term non-progressors/survivors in the remaining cohort (p = 0.0377). The URFs may sometimes spread and become circulating recombinant forms (CRFs) of HIV and local CRF fragments were over-represented in the URF sequences (p < 0.0001). Collectively, our results suggest that CTL-responses associated with beneficial HLA variants likely drive the outgrowth of URFs that might reduce the positive effect of these CTL responses on disease progression.

Indexed as

Genetic VariationRecombination, GeneticSex WorkersAdultDisease ProgressionFemalegag Gene Products, Human Immunodeficiency VirusGenotypeHIV-1HIV Core Protein p24HIV InfectionsHLA AntigensHumansLeukocytes, MononuclearMolecular TypingMutationgag Gene Products, Human Immunodeficiency VirusHIV Core Protein p24HLA Antigens

Identifiers

PMID26082240
PMCPMC4469978
OpenAlexW2411904803

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.